Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Burkitt Lymphoma 20Neoplasm, Residual 9Leukemia 6Lymphoproliferative Disorders 4Lymphoma, Non-Hodgkin 4Lymphatic Diseases 4Leukemia, Biphenotypic, Acute 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Lymphoid 3Recurrence 2Myelodysplastic Syndromes 2Lymphoma 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Immunoproliferative Disorders 2Blast Crisis 2Sarcoma, Myeloid 1Philadelphia-Negative ALL 1Philadelphia Chromosome 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Large Granular Lymphocytic 1Hodgkin Disease 1Hematologic Neoplasms 1Down Syndrome 1

Interventions

Cyclophosphamide 5Rituximab 3fludarabine phosphate 2fludarabine 2dacetuzumab 2cobomarsen 2blinatumomab 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Ifosfamide 2Etoposide 2Doxorubicin 2Carboplatin 2Busulfan 2pembrolizumab 1Vorinostat 1CLR1404 1Brentuximab Vedotin 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Immunoproliferative Disorders × blinatumomab × Clear all
NCT01466179 2017-08-18

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen Research (Munich) GmbH

Phase 2 Completed
225 enrolled 24 charts
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoproliferative Disorders, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01741792 2017-01-06

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Amgen Research (Munich) GmbH

Phase 2 Completed
25 enrolled 18 charts
Lymphoid

Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡